- Home
- Companies
- Gold Standard Diagnostics
- Products
- Model Mplex SARS-CoV-2+, Flu A, Flu B ...
Model Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR - Respiratory Diseases
Respiratory diseases caused by SARS-CoV-2, RSV, and Influenza virus have similar first clinical symptoms, and accurate identification is crucial for better patient care. Gold Standard Diagnostics’ new multiplex assays have been specifically designed to detect and differentiate these viral infections in the same PCR run. The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay allows to differentiate in a single reaction between Influenza A and B, and simultaneously detects two independent gene targets in SARS-CoV-2 (N-gene + RdRP-gene).
- Can be processed in parallel with RSV A, RSV B RT-PCR in the same plate using the same temperature profile
- Validated sample material: nasopharyngeal swab, oropharyngeal swab, nasal wash/swab
- RNaseP used as internal control for sample quality, RNA extraction, and detection of inhibitors
- Fast and reliable results in approximately 1 hour
- Validated thermocyclers: AriaDxTM, AriaMxTM from Agilent Technologies
- CE IVD marked
COVID-19 is the official name for the new infectious disease declared pandemic in March 2020. It is a zoonotic disease that has quickly spread globally from person-to-person via respiratory droplets or through touching contaminated objects or surfa
It can present as an asymptomatic infection, a mild respiratory tract infection, or a severe pneumonia with respiratory failure and even death. The incubation period ranges from 2-14 days (5 days on average), and symptoms can include fever, cough, and shortness of breath.
Primarily transmitted between people through respiratory droplets and contact routes